RFA
BMRN icon

Register Financial Advisors’s BioMarin Pharmaceuticals BMRN Stock Holding History

Register Financial Advisors’s Portfolio BMRN Stock Details BMRN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-34
Closed -$2.97K – 736
2024
Q1 		$2.97K Buy
+34
New +$3.04K ﹤0.01% 656

Other funds holding BMRN

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
Norges Bank
Norges Bank Oslo, Norway $935B AUM

Register Financial Advisors's BMRN Position: Q2 2024 in Review

Register Financial Advisors sold out of BioMarin Pharmaceuticals (BMRN) in Q2 2024, closing a stake of 34 shares — an estimated $2.97K sold.

Register Financial Advisors first reported a position in BMRN in Q1 2024 and held it in 1 quarter. The position peaked at $2.97K in Q1 2024. 558 funds tracked by Wall St. Rank hold BMRN as of Q2 2024.

  • Register Financial Advisors reported no remaining BioMarin Pharmaceuticals position as of Q2 2024 after selling out during the quarter.
  • Register Financial Advisors sold 34 BioMarin Pharmaceuticals shares in Q2 2024, an estimated $2.97K.
  • Register Financial Advisors first reported a position in BioMarin Pharmaceuticals in Q1 2024 and held it in 1 quarter.
  • Register Financial Advisors's BioMarin Pharmaceuticals position peaked at $2.97K in Q1 2024.
  • 558 funds tracked by Wall St. Rank held BioMarin Pharmaceuticals as of Q2 2024.

Based on Register Financial Advisors's 13F filing for Q2 2024, filed 12 Jul 2024.